WO1999018441A1 - Icam-4 and diagnostic uses thereof - Google Patents
Icam-4 and diagnostic uses thereof Download PDFInfo
- Publication number
- WO1999018441A1 WO1999018441A1 PCT/US1998/020876 US9820876W WO9918441A1 WO 1999018441 A1 WO1999018441 A1 WO 1999018441A1 US 9820876 W US9820876 W US 9820876W WO 9918441 A1 WO9918441 A1 WO 9918441A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- icam
- seq
- domain
- rat
- neuropathology
- Prior art date
Links
- 101710148793 Intercellular adhesion molecule 4 Proteins 0.000 claims abstract description 238
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 claims abstract description 236
- 238000000034 method Methods 0.000 claims abstract description 36
- 210000002966 serum Anatomy 0.000 claims description 37
- 230000027455 binding Effects 0.000 claims description 26
- 238000009739 binding Methods 0.000 claims description 26
- 206010012289 Dementia Diseases 0.000 claims description 18
- 230000007171 neuropathology Effects 0.000 claims description 13
- 238000002965 ELISA Methods 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 230000001054 cortical effect Effects 0.000 claims description 4
- 210000001652 frontal lobe Anatomy 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 230000002739 subcortical effect Effects 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 231100000076 Toxic encephalopathy Toxicity 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 208000030212 nutrition disease Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 6
- 241000700159 Rattus Species 0.000 description 86
- 108020004414 DNA Proteins 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 60
- 239000002299 complementary DNA Substances 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 54
- 150000001413 amino acids Chemical group 0.000 description 52
- 230000014509 gene expression Effects 0.000 description 43
- 239000012634 fragment Substances 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 101000599868 Homo sapiens Intercellular adhesion molecule 4 Proteins 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 37
- 102000048962 human ICAM4 Human genes 0.000 description 37
- 239000000523 sample Substances 0.000 description 36
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 31
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 31
- 210000004556 brain Anatomy 0.000 description 28
- 108020001507 fusion proteins Proteins 0.000 description 28
- 102000037865 fusion proteins Human genes 0.000 description 28
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 27
- 238000010367 cloning Methods 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 26
- 239000013598 vector Substances 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 230000003321 amplification Effects 0.000 description 20
- 238000009396 hybridization Methods 0.000 description 20
- 238000003199 nucleic acid amplification method Methods 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 230000004927 fusion Effects 0.000 description 19
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 241000283984 Rodentia Species 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 16
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 16
- 108010070675 Glutathione transferase Proteins 0.000 description 15
- 102000005720 Glutathione transferase Human genes 0.000 description 15
- 238000011144 upstream manufacturing Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 102100025390 Integrin beta-2 Human genes 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000002955 isolation Methods 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 241000701447 unidentified baculovirus Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 210000001320 hippocampus Anatomy 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 10
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 102000043559 human ICAM1 Human genes 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 229920001778 nylon Polymers 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000039966 ICAM family Human genes 0.000 description 5
- 108091069108 ICAM family Proteins 0.000 description 5
- 102100039919 Intercellular adhesion molecule 5 Human genes 0.000 description 5
- 101710148796 Intercellular adhesion molecule 5 Proteins 0.000 description 5
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 5
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 5
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 102000023732 binding proteins Human genes 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000005220 cytoplasmic tail Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001587 telencephalon Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000058166 human ICAM3 Human genes 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000001535 kindling effect Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 101000599858 Homo sapiens Intercellular adhesion molecule 2 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 101000599859 Rattus norvegicus Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000056475 human ICAM2 Human genes 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- -1 OCT compound Chemical class 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101150046625 RRD2 gene Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 206010063661 Vascular encephalopathy Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000005016 dendritic process Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101500024558 Homo sapiens Pancreatic icosapeptide Proteins 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101000962498 Macropis fulvipes Macropin Proteins 0.000 description 1
- 101000599863 Mus musculus Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 241001437938 Proceps Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 101100452016 Rattus norvegicus Icam1 gene Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical class BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000030294 homotypic cell-cell adhesion Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 230000008043 neural expression Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
Definitions
- the present invention relates generally to cellular adhesion molecules and more particularly to the cloning and expression of DNA encoding a heretofore unknown polypeptide designated "ICAM-4" which possesses structural relatedness to the intercellular adhesion molecules ICAM-
- CAMs Cell surface proteins, and especially the so-called Cellular Adhesion Molecules (“CAMs”) have correspondingly been the subject of pharmaceutical research and development having as its goal intervention in the processes of leukocyte extravasation to sites of inflammation and leukocyte movement to distinct target tissues, as well as neuronal differentiation and formation of complex neuronal circuitry.
- the isolation and characterization of cellular adhesion molecules, the cloning and expression of DNA sequences encoding such molecules, and the development of therapeutic and diagnostic agents relevant to inflammatory processes and development and function of the nervous system have also been the subject of numerous U.S. and foreign applications for Letters Patent. See Edwards, Current Opinion in Therapeutic Patents, 1(11): 1617-1630 (1991) and particularly the published "patent literature references” cited therein.
- CD18/CDl la referred to in WHO nomenclature as CD18/CDl la, CD18/CDl lb, and CD18/CDl lc, respectively
- CD18/CDl la referred to in WHO nomenclature as CD18/CDl la, CD18/CDl lb, and CD18/CDl lc, respectively
- integral cell surface proteins present on B lymphocytes, T lymphocytes, monocyies and granulocytes. See, e.g. , Table 1 of Springer, supra, at page
- CAMs single chain adhesion molecules
- LFA-1 two distinct intercellu- lar adhesion molecules
- ICAM-2 two distinct intercellu- lar adhesion molecules
- ICAM-1 and ICAM-2 are structurally homologous to other members of the immunoglobulin gene superfamily in that the extracellular portion of each is comprised of a series of domains sharing a similar carboxy terminal motif.
- a "typical" immunoglobulin-like domain contains a loop structure usually anchored by a disulfide bond between two cysteines at the extremity of each loop.
- ICAM-1 includes five immunoglobulin-like domains; ICAM-2, which differs from ICAM-1 in terms of cell distribution, includes two such domains; PECAM-1 includes six; VCAM includes six or seven, depending on splice variations, and so on.
- CAMs typically include a hydrophobic "transmembrane" region believed to participate in orientation of the molecule at the cell surface and a carboxy terminal "cytoplasmic" region.
- Graphic models of the operative disposition of CAMs generally show the molecule anchored in the cell membrane at the transmembrane region with the cytoplasmic "tail" extending into the cell cytoplasm and one or more immunoglobulin-like loops extending outward from the cell surface.
- a number of neuronal cells express surface receptors with extracellular Ig-like domains, structurally similarity to the ICAMs. See for example, Yoshihara, et al. , supra.
- many adhesion molecules of the nervous system also contain tandemly repeated fibronectin-like sequences in the extracellular domain.
- W091/16928 published November 14, 1991, for example, addresses humanized chimeric anti-ICAM-1 antibodies and their use in treatment of specific and non-specific inflammation, viral infection and asthma.
- Anti- ICAM-1 antibodies and fragments thereof are described as useful in treatment of endotoxic shock in WO92/04034, published March 19, 1992.
- Inhibition of ICAM-1 dependent inflammatory responses with anti-ICAM-1 anti-idiotypic antibodies and antibody fragments is addressed in WO92/06119, published April 16, 1992.
- WO92/06119 published April 16, 1992.
- ICAM-like surface molecule which has a tissue specific expression unlike that of any known ICAM molecule.
- Mori, et al. [Proc.Natl.Acad.Sci. (USA) 54:3921-3925 (1987)] reported identification of a telencephalon-specific antigen in rabbit brain, specifically immunoreactive with monoclonal antibody 271A6. This surface antigen was named telencephalin. Imamura, et al. , [Neurosci. Letts.
- telencephalin expression was variable as a function of development.
- Oka, et al. [Neuroscience 55:93-103 (1990)] subsequently reported isolation of telencephalin using monoclonal antibody 271A6.
- the publication reports a molecular weight for the surface molecule of about 500 kD and that the molecule was composed of four subunits, each with a native molecular weight of 130 kD and approximately 100 kD following N-glycanase treatment.
- the present invention provides purified and isolated polynucleotides (e.g. , DNA sequences, RNA transcripts and anti- sense oligonucleotides thereof) encoding a novel polypeptide, "ICAM-4," as well as polypeptide variants (including fragments and deletion, substitution, and addition analogs) thereof which display one or more ligand/receptor binding biological activities and/or immunological properties specific to ICAM-4.
- ICAM-4-specific ligand/receptor binding biological activities encompass interactions of both the ICAM-4 extracellular and cytoplasmic domains with other molecules (e.g. , in processes of cell-cell adhesion and/or signal transduction).
- Preferred DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences.
- a presently preferred polynucleotide is set out in SEQ ID NO: 1 and encodes rat species ICAM-4.
- Biological replicas i.e. , copies of isolated DNA sequences made in vivo or in vitro
- DNA sequences of the invention are contemplated.
- autonomously replicating recombinant constructions such as plasmid and viral DNA vectors incorporating ICAM-4 sequences and especially vectors wherein DNA encoding ICAM-4 or an ICAM-4 variant is operatively linked to an endoge- lawn or exogenous expression control DNA sequence.
- host cells especially unicellular host cells such as procaryotic and eucaryotic cells, are stably transformed with DNA sequences of the invention in a manner allowing the desired polypeptides to be expressed therein.
- Host cells expressing such ICAM-4 and ICAM-4 variant products can serve a variety of useful purposes. To the extent that the expressed products are "displayed" on host cell surfaces, the cells may constitute a valuable immunogen for the development of antibody substances specifically immunoreactive with ICAM-4 and ICAM-4 variants.
- Host cells of the invention are conspicuously useful in methods for the large scale production of ICAM-4 and ICAM-4 variants wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown.
- Novel ICAM-4 of the invention may be obtained as isolates from natural cell sources, but, along with ICAM-4 variant products, are preferably produced by recombinant procedures involving host cells of the invention.
- a presently preferred amino acid sequence for an ICAM-4 polypeptide is set out in SEQ ID NO: 2.
- ICAM-4 variants of the invention may comprise water soluble or insoluble monomeric, multimeric or cyclic ICAM-4 fragments which include all or part of one or more of the domain regions specified above and having a biological or immunological property of ICAM-4 including, e.g. , the ability to bind to a binding partner of ICAM-4 and/or inhibit binding of ICAM-4 to a natural binding partner.
- ICAM-4 variants of the invention may also comprise polypeptide analogs wherein one or more of the specified amino acids is deleted or replaced: (1) without loss, and preferably with enhancement, of one or more biological activities or immunological characteristics specific for ICAM-4; or (2) with specific disablement of a particular ligand/receptor binding function.
- Analog polypeptides including additional amino acid (e.g. , lysine or cysteine) residues that facilitate multimer formation are contemplated.
- antibody substances e.g. , monoclonal and polyclonal antibodies, antibody fragments, single chain antibodies, chimeric antibodies, CDR-grafted antibodies and the like
- other binding proteins e.g. , polypeptides and peptides
- the invention also comprehends hybridoma cell lines which specifically secrete monoclonal antibodies of the invention.
- Presently preferred hybridomas of the invention include those designated 127A, 127H, 173E, 1791, and 179H.
- Antibody substances can be developed using isolated natural or recombinant ICAM-4 or ICAM-4 variants or cells expressing such products on their surfaces. Binding proteins of the invention are additionally useful for characterization of binding site structure(s) (e.g. , epitopes and/or sensitivity of binding properties to modifications in ICAM-4 amino acid sequence).
- Binding proteins are useful, in turn, in compositions for immunization as well as for purifying polypeptides of the invention and identifying cells displaying the polypeptides on their surfaces. They are also manifestly useful in modulating (i.e. , blocking, inhibiting or stimulating) ligand/receptor binding biological activities involving ICAM-4, especially those ICAM-4 effector functions involved in specific and non-specific immune system responses. Anti-idiotypic antibodies specific for anti-ICAM-4 antibody substances and uses of such anti-idiotypic antibody substances in modulating immune responses are also contemplated.
- the invention further provides methods of screening for neuropathology in an individual comprising the steps of: a) obtaining a fluid sample from the individual; b) contacting the sample with an antibody specifically immunoreactive with ICAM-4; c) quantitating the level of ICAM-4/antibody binding in the sample; and d) comparing the level of IC AM-4/antibody binding in the sample to the level of ICAM-4/antibody binding in individuals (controls) known to be free of the neuropathology.
- Assays for the detection and quantification of ICAM-4 on cell surfaces and in body fluids, such as serum or cerebrospinal fluid may involve, for example, a single antibody substance or multiple antibody substances in a "sandwich" assay format.
- antibodies of the invention are also useful for assessing the occurrence of neuropathologies which can be correlated to increased levels of circulating ICAM-4.
- neuropathologies include, but are not limited to, cerebral ischemia (i.e. , stroke) resulting from various disorders including, for example, thrombosis, embolism, cerebral aneurysmal hemorrhage, vasospasm, and the like.
- Quantitation of circulating ICAM-4 can also distinguish between various forms of epilepsy and may also permit determination of the stage of AIDS progression.
- Still other neurodegenerative disorders for which measurement of circulating ICAM-4 can be useful for diagnosis include various forms of Alzheimer's disease and other cortical dementias (such as Pick's disease, diffuse cortical Lewy body disease, and frontal lobe degeneracy), subcortical dementias (including Parkinson's disease, Huntington's disease, and progressive supranuclear), a number of the primary psychiatric disorders (such as depression, schizophrenia and psychosis), as well as nongenetic dementias arising from, for example, infections, vasculitis, metabolic and nutritional disorders (e.g. , thyroid, vitamin B12 deficiency), vascular disorders (multiple infarct, lacunar state, Binswanger's disease), toxic encephalopathies (e.g. , exposure to carbon monoxide, heavy metals or other industrial pollutants) and tumors.
- cortical dementias such as Pick's disease, diffuse cortical Lewy body disease, and frontal lobe degeneracy
- DNA and amino acid sequences of the present invention are manifest.
- knowledge of the sequence of a cDNA for ICAM-4 makes possible the isolation by DNA/DNA hybridization of genomic DNA sequences encoding ICAM-4 and specifying ICAM-4 expression control regulatory sequences such as promoters, operators and the like.
- DNA/DNA hybridization procedures carried out with DNA sequences of the invention and under stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of ICAM-4, other structurally related proteins sharing one or more of the biological and/or immunological properties specific to ICAM-4, and proteins homologous to ICAM-4 from other species.
- DNAs of the invention are useful in DNA/RNA hybridization assays to detect the capacity of cells to synthesize ICAM-4. Also made available by the invention are anti-sense polynucleotides relevant to regulating expression of ICAM-4 by those cells which ordinarily express the same.
- knowledge of the DNA and amino acid sequences of ICAM-4 makes possible the generation by recombinant means of ICAM-4 variants such as hybrid fusion proteins (sometimes referred to as "immuno- adhesions”) characterized by the presence of ICAM-4 protein sequences and immunoglobulin heavy chain constant regions and/or hinge regions. See, Capon etal. , Nature, 337: 525-531 (1989); Ashkenazi et al.
- ICAM-4 variant fusion proteins may also include, for example, selected extracellular domains of ICAM-4 and portions of other cell adhesion molecules.
- DNA of the invention also permits identification of untranslated DNA sequences which specifically promote expression of polynucleotides operatively linked to the promoter regions. Identification and use of such promoter sequences are particularly desirable in instances, for example gene transfer, which can specifically require heterologous gene expression in a limited neuronal environment.
- the invention also comprehends vectors comprising promoters of the invention, as well as chimeric gene constructs wherein the promoter of the invention is operatively linked to a heterologous polynucleotide sequence and a transcription termination signal.
- the DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of ICAM-4 and definition of those molecules with which it will interact on extracellular and intracellular levels.
- the idiotypes of anti-ICAM- 4 monoclonal antibodies of the invention are representative of such molecules and may mimic natural binding proteins (peptides and polypeptides) through which ICAM-4 intercellular and intracellular activities are modulated or by which ICAM-4 modulates intercellular and intracellular events. Alternately, they may represent new classes of modulators of ICAM-4 activities.
- Anti- idiotypic antibodies in turn, may represent new classes of biologically active ICAM-4 equivalents.
- In vitro assays for identifying antibodies or other compounds that modulate the activity of ICAM-4 may involve, for example, immobilizing ICAM-4 or a natural ligand to which ICAM-4 binds, detectably labelling the nonimmobilized binding partner, incubating the binding partners together and determining the effect of a test compound on the amount of label bound wherein a reduction in the label bound in the presence of the test compound compared to the amount of label bound in the absence of the test compound indicates that the test agent is an inhibitor of ICAM-4 binding.
- the DNA sequence information provided by the present invention also makes possible the development, by homologous recombination or "knockout” strategies [see, e.g. , Kapecchi, Science, 244: 1288-1292 (1989)], of rodents that fail to express a functional ICAM-4 protein or that express a variant ICAM-4 protein. Such rodents are useful as models for studying the activities of ICAM-4 and ICAM-4 modulators in vivo.
- a first rodent genomic ICAM-4 sequence was identified which encoded a region homologous to domain 2 (herein SEQ ID NO: 3, and SEQ ID NO: 23 of U.S.S.N. 08/102,852) of human ICAM-R (herein as SEQ ID NO: 4).
- a second, overlapping genomic DNA (herein SEQ ID NO: 5, and SEQ ID NO: 26 of U.S.S.N. 08/102,852) was also identified which encoded both the domain 2 region of SEQ ID NO: 3, and sequences for ICAM-1.
- a rodent spleen cDNA (herein SEQ ID NO: 6, and SEQ ID NO: 25 in U.S.S.N. 08/102,852) was identified which encoded domains 2 through 5 as well as a fifth domain not previously observed as an ICAM domain.
- these newly identified rodent DNAs appeared to encode a rodent homolog of human ICAM-R, however alignment of 3 ' regions of these DNAs with other ICAMs proved difficult.
- the subsequent isolation of a 1 kb cDNA clone from a rat spleen library, and amplification of an RT-PCR fragment indicated that a portion of both the cDNA and genomic clones had not been sequenced.
- SEQ ID NO: 7 Another RT-PCR amplification product (SEQ ID NO: 7) confirmed this omission. It was determined that a fragment of 177 bp was excised from the genomic and cDNA clones by EcoRl digestion of the clones to isolate these sequences from ⁇ phage for DNA sequencing studies. Reanalysis of SEQ ID NOs: 5 and 6 in light of these other sequences permitted identification of more accurate and complete sequences for the originally isolated genomic and cDNA clones, presented in corrected form herein as SEQ ID NOs: 8 and 9.
- a rat brain cDNA (SEQ ID NO: 10) was isolated, and 5 ' end sequence determined by 5 ' rapid amplification of cDNA ends (5 ' RACE), the amplification product set forth in SEQ ID NO: 11.
- RACE 5 ' rapid amplification of cDNA ends
- SEQ ID NO: 11 Combining information from the RT-PCR clone (SEQ ID NO: 7), the brain cDNA (SEQ ID NO: 10) and the RACE amplification product (SEQ ID NO: 11) permitted identification of the complete coding sequence for ICAM-4 (SEQ ID NO: 1).
- Example 1 addresses cloning of a partial rodent ICAM-4 DNA.
- Example 2 describes Northern blot analysis of rodent ICAM- 4 transcription.
- Example 3 describes isolation of a full length rodent ICAM-4 cDNA.
- Example 4 relates the in situ hybridization of rodent ICAM-4 in brain tissue.
- Example 5 addresses generation of ICAM-4 fusion proteins in prokaryotes.
- Example 6 describes production of monoclonal antibodies specific for rat ICAM-4/GST fusion proteins.
- Example 7 describes expression of soluble rat ICAM-4 proteins in a baculovirus expression system.
- Example 8 addresses production of monoclonal antibodies specific for rat ICAM-4 expressed in a baculovirus system.
- Example 9 describes immunocytochemical analysis of rat ICAM-4 expression.
- Example 10 relates cloning of a human genomic ICAM-4-encoding DNA.
- Example 11 addresses cloning of a human ICAM-4-encoding cDNA.
- Example 12 describes Northern analysis of human ICAM-4 expression.
- Example 13 describes generation of human ICAM- 4/GST fusion proteins.
- Example 14 addresses production of monoclonal antibodies immunospecific for human ICAM-4.
- Example 15 describes development of a capture assay for determining the concentration of soluble ICAM-4 in a particular fluid.
- Example 16 applies the capture assay method in assessing ICAM-4 concentration in the serum of stroke patients.
- Example 17 relates to assessment of ICAM-4 transcription in a rat epilepsy model.
- Example 18 describes measurement of circulating ICAM-4 concentration as an assessment of various neurodegenerative disorders.
- Example 19 addresses cloning of a promoter region for human ICAM-4.
- a rat genomic library constructed in ⁇ EMBL3 was screened a with [ 32 P]-labeled probe generated by PCR from DNA encoding human ICAM-3 domain 2 The sequence of the probe is set forth in SEQ ID NO: 12.
- Library plaques were transferred to Hybond N+ nylon membranes (Amersham, Arlington Heights, IL). Screening of all cDNA and genomic libraries was performed according to standard protocols. Prehybridization and hybridizations were carried out in a solution of 40-50% formamide, 5X Denhardt's, 5X SSPE and 1.0% SDS at 42°C. Probes ([ 32 P]-labeled) were added at a concentration of 10 5 -10 6 cpm/ml of hybridization solution.
- nylon membranes were washed extensively at room temperature in 2X SSPE with 0.1 % SDS and subsequently exposed to X-ray film at -80°C overnight. Positive plaques were subjected to one or more rounds of hybridization to obtain clonal phage. DNA prepared from lysate of the positive clones was subcloned into pBS- .and sequenced.
- a first genomic clone encoding a rat ICAM-related domain 2 was identified that was determined to be homologous to domain 2 regions in other ICAM family members (see for example. Table 1 of U.S. Patent
- a second, overlapping clone was also identified with the same probes and was determined to contain the ICAM domain 2 sequence of SEQ ID NO: 3 and 5 ' DNA encoding at least part of rat ICAM-1.
- the nucleic acid sequence for this clone was set forth in the co-pending parent to the present application as SEQ ID NO: 26 and is set forth herein as SEQ ID NO: 5.
- This second clone indicated that the ICAM-related gene fragment of the first clone and the gene encoding rat ICAM-1 are located on the same rat chromosome within 5 kb of each other.
- [ 32 P]-labeled DNA encoding the domain 2 sequence from the rat genomic clone identified in Section A was used to screen a number of cDNA libraries from various rat and mouse cell types, including rat macrophage (Clontech, Palo Alto, CA), peripheral blood lymphocyte (PBL) (Clontech), T cell (constructed in-house), and spleen (Clontech), and mouse PBL (Clontech), T cell (constructed in- house), and B cell (constructed in-house).
- PBL peripheral blood lymphocyte
- T cell constructed in-house
- spleen Clontech
- mouse PBL mouse PBL
- nucleic acid sequence for this clone was set forth in the parent to the present application as SEQ ID NO: 25; herein the nucleic acid sequence for this spleen cDNA clone is set forth in SEQ ID NO: 6.
- the 177 bp EcoRI fragment is situated between nucleotides 719 and 896 in the rat partial cDNA clone as set out in S ⁇ Q ID NO: 9 and between nucleotides 2812 and 2989 in the partial genomic clone as set out in S ⁇ Q ID NO: 8.
- RT-PCR was utilized to generate more complete sequence information for the rat ICAM-related gene.
- Sequence information from the genomic clone (S ⁇ Q ID NO: 3) was used to design sense primers complementary to a region 5 ' of the protein coding region, as determined from the cDNA clone, and antisense primers designed complementary to coding sequences and regions 3 ' to the coding sequence in the cDNA clone (SEQ ID NO: 6).
- Template cDNA for PCR reactions was prepared as follows. Approximately 2 ⁇ g of poly A + RNA isolated from rat spleen cells was denatured by heating at 65 °C in a 10 ⁇ l volume. Following denaturation, 0.1 ⁇ RNasin (Invitrogen, San Diego, CA), 5 ⁇ l 5X RTase Buffer (BRL, Bethesda, MD), 2 ⁇ l random hexamer (pd(N)6 at 100 ⁇ g/ml) (Pharmacia, Piscataway, NJ), 6 ⁇ l dNTPs (2 mM each) and 2 ⁇ l AMV RTase (BRL) were added and the reaction was incubated at 42 °C for 60-90 min. Reactions were stored at -20 °C until needed.
- primer RRD2 3-1 corresponded to nucleotides 719 through 736.
- various 3 ' antisense primers were paired with a 5 ' primer designed complementary to another internal, coding sequence; the 5 ' primer in these reactions was designated RGen3900S and is set forth in SEQ ID NO: 17.
- ACGGAATTCGAAGCCATCAACGCCAGG (SEQ ID NO: 17) (In SEQ ID NO: 7, infra, primer RGen3900S corresponded to nucleotides 1719 through 1736.) Based on the size of the amplification products and the ability of these products to hybridize with the partial cDNA clone, one pair of primers was determined to be most efficient and was used in subsequent PCR amplifications.
- the 5 ' primer was designated RGen780S (SEQ ID NO: 18) and the 3 ' primer was designated RGen4550AS (SEQ ID NO: 19).
- CATGAATTCCGAATCTTGAGTGGGATG (SEQ ID NO: 18)
- primer RGen780S corresponded to nucleotides 1 through 18, and primer RGen4550AS corresponded to nucleotides 2197 through 2214.
- This primer pair was used in PCR under a variety of conditions to optimize amplification.
- a total of 15 different PCR buffers that varied in pH and Mg + + concentration were used at two different annealing temperatures, and a sample of the product from each reaction was separated on a 1 % agarose gel. Because no amplification product could be detected by visual inspection of the ethidium bromide stained gel from any of the reaction conditions, more sensitive Southern hybridization was employed to detect the PCR products.
- the 2.2 kb region was eluted from the gel, even though no band was evident upon visual inspection, and used as a template in another PCR reaction using the same primers (SEQ ID NOs: 18 and 19), Tris-HCl buffer, pH 8.0, conUuning 1 mM Mg + + , and 55 °C annealing temperature.
- the amplification product from the secondary PCR was visible in the gel and was eluted and cloned into a pBS + plasmid (Stratagene, La Jolla, CA) for sequence analysis.
- the resulting RT-PCR clone was determined to contain 2214 bp as set forth in SEQ ID NO: 7.
- the clone encoded domains 2 through 6 found in the rat spleen cDNA clone, an additional amino terminal domain 1 , an additional carboxy terminal domain 7, and 164 bp of what appeared to be a further carboxy terminal domain 8.
- Immediately 5 ' to domain 1 was an additional 144 bp sequence presumed to have been derived from an intron between the leader and the first domain.
- This clone did not contain a 5 ' leader sequence or 3 ' transmembrane and cytoplasmic regions.
- the 7th and 8th domains in the RT-PCR clone supported the hypothesis that this clone was a novel rodent ICAM.
- Example 1 In order to further investigate the possibility that the ICAM- related clones identified in Example 1 encoded a novel ICAM polypeptide as suggested by the unique Ig-like domains, tissue specific expression was examined by Northern blot analysis to permit comparison with the previously reported expression patterns of human ICAMs [ICAM-1 , Dustin, et al , J. Immunol. 137:245-254 (1986); ICAM-2, Staunton, et al. , Nature 339:6 -64 (1989); ICAM-R, de Fourgerolles and Springer, J.Exp.Med. 775: 185-190 (1992)].
- ICAM-1 Dustin, et al , J. Immunol. 137:245-254 (1986); ICAM-2, Staunton, et al. , Nature 339:6 -64 (1989); ICAM-R, de Fourgerolles and Springer, J.Exp.Med. 775: 185-190 (1992)].
- RNA from rat lung, brain, spinal cord, liver, digestive tract, thymus, lymph nodes, and spleen was prepared using STAT60 RNA isolation reagents (Tel-test "B", Ine, Friendswood, Texas) according to the manufacturer's suggested protocol. Poly A + RNA was purified from total RNA using oligo dT cellulose columns. Approximately 5 ⁇ g of RNA derived from each tissue was separated on a 1 % formaldehyde agarose gel, and transferred to hybond-C nitrocellulose membranes (Amersham).
- the membrane- bound RNA was prehybridized in a solution containing 50% formamide, 5X SSC, IX PE (50 mM Tris-HCl, pH 7.5, 0.1 % sodium pyrophosphate, 0.2 % polyvinylpyrrolidone, 0.2% ficoll, 5 mM EDTA, 1 % SDS) and 150 ⁇ g/ml denatured salmon sperm DNA.
- the radiolabeled probe was denatured by boiling and added to the prehybridization solution to a final concentration of 1 x 10 6 cpm/ml. Hybridization was allowed to proceed for 16-18 hours at 65 °C.
- Example 1 The membranes were then washed at 65 °C in 2X SSC containing 0.1 % SDS and subsequently exposed to X-ray film for 3-16 hours.
- the Northern blot analysis indicated that the ICAM-related cDNA identified in Example 1 was expressed only in rat brain, a tissue specificity not previously reported for any other ICAM polypeptides.
- This expression pattern in combination with the unique Ig-like domains not known to exist in other ICAM polypeptides, indicated that the ICAM-related clone was a novel member of the ICAM family of proteins, and was named ICAM- 4.
- Example 1 brain tissue mRNA was utilized in an attempt to isolate a full length cDNA encoding ICAM-4.
- Two probes one complementary to domains 1 through 2 and a second complementary to domains 3 through 5 of the spleen cDNA clone identified in Example 1 (SEQ ID NO: 7), were radiolabeled and used to screen a rat brain cDNA library in ⁇ gtlO which was previously constructed in-house.
- Hybridization conditions were as described in Example 1 , and positive plaques were subjected to one or more rounds of screening to obtain clonal phage.
- clone 7 Nine positive clones were identified, two of which hybridized to both probes. The longest of the two clones, designated clone 7, contained 2550 bp encoding four of the five Ig-like domains found in the probe cDNA. In addition, clone 7 encoded four other Ig-like domains not found in the probe. Putative transmembrane and cytoplasmic domains were identified which were followed by a stop codon, a poly-adenylation signal, and a poly A tail.
- Clone 7 was lacking at least one 5 ' Ig-like domain as determined by comparison to the RT-PCR clone (SEQ ID NO: 7), and also lacked a leader sequence; re-screening of the library did not yield any longer clones which contained these sequences.
- the nucleic acid sequence for clone 7 is set forth in SEQ ID NO: 10.
- RACE-ready cDNA from rat brain (supplied with kit) was used in a PCR with the kit oligonucleotide and an antisense primer based on an internal ICAM-4 sequence.
- the 3 ' antisense primer, designated Spot714AS was designed according to an ICAM-4 domain 4 sequence and is set forth in SEQ ID NO: 20.
- CARGGTGACAAGGGCTCG (SEQ ID NO: 20)
- the amplification product resulting from this primer pair was subsequently subjected to a secondary PCR using the same 5 ' kit primer paired with a 3 ' primer complementary to a region in ICAM-4 domain 1.
- the second 3 ' primer was designated RRACE2 and is set forth in SEQ ID NO: 21.
- Each primer used in the secondary PCR contained an EcoRI site to facilitate cloning of the resulting amplification products into pBS + (Stratagene).
- the resulting plasmid DNA which contained the 5 ' end of the gene was identified by hybridization to a rat ICAM-4 domains 1 and 2 probe, corresponding to nucleotides 1 through 736 in S ⁇ Q ID NO: 7. Partial sequence information for domain 1 and the hydrophobic leader was determined from the resulting amplification product.
- the product from the 5 ' RACE method was a DNA fragment 222 bp long containing 60 bp upstream of the initiating methionine residue, an 82 bp leader sequence, and an 80 bp sequence from domain 1.
- the amplification product is set forth in SEQ ID NO: 11.
- a composite clone of the full length ICAM-4 was constructed from the sequence information derived from the 5 ' RACE method (SEQ ID NO: 11), the RT-PCR clone (SEQ ID NO: 7) and the brain cDNA clone 7 (SEQ ID NO: 10).
- the full length gene for rat ICAM-4 was determined to contain 2985 bp with a single open reading frame encoding a deduced 917 amino acid protein.
- a putative Kozak sequence is located upstream of the methionine residue in the leader sequence.
- a 27 amino acid hydrophobic leader sequence is followed by nine Ig-like domains, a transmembrane region and a 58 amino acid cytoplasmic tail.
- the composite ICAM-4 cDNA is set for in SEQ ID NO: 1
- the deduced amino acid sequence is set forth in SEQ ID NO: 2.
- ICAM-4 contains extracellular, transmembrane, and cytoplasmic domains.
- the amino terminus of ICAM-4 is a leader sequence comprising amino acids 1 through 27 which is followed by nine immunoglobulin (Ig)-like domains, a characteristic unique to ICAM-4 in that ICAM-1 , ICAM-2, and ICAM-R contain five, two, and five extracellular Ig-like domain, respectively.
- Ig immunoglobulin
- ICAM-4 Intracellular cellular fibroblasts 743 through 830.
- a characteristic "loop" structure is formed by a disulfide bond between cysteine residues located generally at opposite ends of the domain amino acid sequence.
- Other structural features of ICAM-4 include the transmembrane region comprising amino acids 831 through 859 and the cytoplasmic region comprising amino acids 860 through
- rat ICAM-4 domains 6 through 8 are most homologous with domain 5 (ranging from 29-42% identical), possibly arising from a gene segment duplication event.
- the ninth and final extracellular domain aligns poorly with other ICAM domains but has 22 % identity with the 3rd and 6th domains of human VCAM-1 , another member of the Ig family of protein which participate in cell adhesion.
- the cytoplasmic tail is 58 amino acids long. This is longer than the other members of the ICAM family wherein human ICAM-1 , -2, and -3 contain 28, 26, and 37 amino acids, respectively.
- rat ICAM-4 cytoplasmic tail is most homologous with the cytoplasmic tail of human VCAM-1 , which contains only 19 amino acids.
- ICAM-4 domain 1 and ICAM-4 domains 3 through 4 anti-sense ribop robes were employed.
- the probes were labeled by in vitro transcription using 35 S-labeled UTP.
- Frozen tissue sections of normal rat brain were fixed in 4% paraformaldehyde for 20 minutes, rinsed and dehydrated, and the fixed RNA denatured for 2 minutes in 2X SSC, 70% formamide at 70°C prior to hybridization.
- Tissue sections were hybridized overnight at 50°C in a solution containing 50% formamide, 0.3 M NaCl, 20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10% dextran sulfate, IX Denhardt, 0.5 mg/ml yeast RNA, 100 mM DTT and a probe concentration of 50,000 cp / ⁇ l.
- the signal detected in brain tissue was primarily, localized in the gray matter with the strongest signal in the cerebral cortex and hippocampus.
- the hybridization profile was consistent with ICAM-4 expression primarily in cerebral neurons.
- Rat ICAM-4/glutathione S-transferase (GST) fusion proteins were generated using the prokaryote expression vector pGEX (Pharmacia, Alameda, CA) in order to generate monoclonal antibodies against specific ICAM-4 polypeptide fragments.
- PCR primers corresponding to the 5 ' and 3 ' ends of domain 1 and the 5 ' and 3 ' ends of domain 2 were used to amplify DNA fragments encoding the individual domains.
- the resulting fragments were separately cloned into an EcoRI site of pG ⁇ X-2T; DNA sequence analysis confirmed the correct orientation and reading frame. Transformants were subsequently screened for their ability to produce fusion protein of the appropriate molecular weight.
- ICAM-4 domain 1/GST and ICAM-4 domain 2/GST fusion proteins remained in the insoluble fraction after the bacteria were lysed by sonication in PBS containing 1 % SDS.
- the insoluble protein fraction from 100 ml cultures were boiled in SDS loading dye and separated on a 10% preparative polyacrylamide-SDS gel. The gel was stained in ice cold 0.4 M KC1 and the fusion protein bands were excised. Fusion proteins were electroeluted from the gel slices in dialysis tubing in buffer containing 25 mM Tris-HCl and 192 mM glycine. Approximate protein concentration was determined by OD 2 go and purity of the preparation was determined on SDS- PAGE stained with Coomassie blue.
- mice were immunized by subcutaneous injection with
- mice 40-50 ⁇ g ICAM-4 domain-2/GST fusion protein (described in Example 5) emulsified in Freund's complete adjuvant (FCA).
- FCA Freund's complete adjuvant
- the mice were again immunized by subcutaneous injection with the same protein, emulsified however in Freund's incomplete adjuvant.
- Two final intraperitone- al immunizations given two weeks after the second immunization included soluble antigen with no adjuvant given at two week intervals. Serum from each immunized mouse was assayed by ELISA for its ability to specifically react with rat ICAM-4 produced by the baculovirus expression system described infra.
- the spleen from mouse #1654 was sterilely removed and placed in 10 ml serum-free RPMI 1640.
- a single-cell suspension was formed by grinding the spleen tissue between frosted ends of two glass microscope slides submerged in serum free RPMI 1640 (Gibco, Burlington, Ottawa, Canada) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin.
- the cell suspension was filtered through a sterile 70-mesh Nitex cell strainer (Becton Dickinson, Parsippany, NJ), and washed twice with RPMI followed by centrifuging at 200 x g for 5 minutes.
- the resulting pellet from the final wash was resuspended in 20 ml serum-free RPMI.
- Thymocytes taken from three naive Balb/c mice were prepared in an identical manner.
- NS-1 myeloma cells Prior to fusion, NS-1 myeloma cells were maintained in log phase growth in RPMI with 11 % Fetalclone serum (FBS) (Hyclone Laborato- ries, Logan, Utah) for three days. Once harvested, the cells were centrifuged at 200 x g for 5 minutes, and the pellet was washed twice as described in the foregoing paragraph. After washing, the cell suspension was brought to a final volume of 10 ml in serum free RPMI.
- FBS Fetalclone serum
- the resulting pellet was dislodged by tapping the tube and 2 ml of 50% PEG 1500 in 75 mM Hepes, pH 8.0, (Boehringer Mannheim, Indianapolis, IN) was added with stirring over the course of 1 minute. Subsequently, an additional 14 ml serum free RPMI was added over 7 minutes. The cell suspension was centrifuged at 200 x g for 10 minutes and the supernatant discarded.
- the pellet was resuspended in 200 ml RPMI containing 15% FBS, 100 ⁇ M sodium hypoxanthine, 0.4 ⁇ M aminopterin, 16 ⁇ M thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5 x 10 6 thymocytes/ml.
- the suspension was first placed in a 225 cm 2 flask (Corning, Essex, United Kingdom) at 37°C for four hours before being dispensed into ten 96-well flat bottom tissue culture plates (Corning) at 200 ⁇ l/well.
- Cells in the plates were fed on days 3, 4, 5, and 6 post fusion by aspirating approximately 100 ⁇ l from each well with a 20 G needle (Becton Dickinson), and adding 100 ⁇ l/well plating medium described above except containing 10 units/ml IL-6 and lacking thymocytes.
- the fusion plates were screened initially by antigen capture ELISA as follows. Immulon 4 plates (Dynatech, Cambridge, MA) were coated overnight at 4°C with 100 ng/well of either domain 1-GST or domain 2-GST fusion protein in 50 mM carbonate buffer. The plates were blocked with 100 ⁇ l/well 0.5 % fish skin gelatin (Sigma, St. Louis, MO) in PBS for 30 minutes at 37°C. After blocking, the plates were washed 3X with PBS containing 0.05 % Tween 20 (PBST) and 50 ⁇ l/well of hybridoma supernatant from each fusion was added.
- PBST 0.05 % Tween 20
- the monoclonal antibodies produced by the hybridomas were isotyped by ELISA.
- Immulon 4 plates (Dynatech) were coated at 4°C with 50 ⁇ l/well goat anti-mouse IgA, IgG, or IgM (Organon Teknika, Durham, NC) diluted 1 :5000 in 50 mM carbonate buffer, pH 9.6.
- Wells were blocked for 30 minutes at 37°C with 1 % BSA in PBS, washed 3X with PBST.
- a 1 : 10 dilution of hybridoma culture supernatant (50 ⁇ l) was added to each plate, incubated, and washed as above.
- ICAM-1 /ICAM-4 expression plasmid Rat ICAM-1 DNA encoding the five Ig-like domains was amplified by PCR using primers which incoiporated several features to facilitate construction of the fusion plasmid.
- the 5 ' oligonucleotide primer included Hindm and Bgl ⁇ .
- the 3 ' oligonucleotide primer included a coding sequence for six histidines followed by a stop codon and a Hindm cloning site.
- the PCR amplification product was cloned into a H/n ⁇ II-digested pBS + vector and sequence analysis confirmed the appropriate construction.
- An internal Smal site in the ICAM-1 leader sequence and another S/?z ⁇ I site in the vector's multiple cloning region (3 ' to ICAM-1 Ig-like domain 5) were digested which removed most of the ICAM-1 coding sequence.
- the linearized, blunt-ended vector contained a portion of the upstream multiple cloning region (those restriction sites 5 ' of the original Hindm site in the multiple cloning region), the Kozak sequence and most of the ICAM-1 leader sequence.
- the coding sequence for rat ICAM-4 domains 1 through 6 was amplified by PCR utilizing primers designed to permit cloning of this sequence into the linearized vector described above.
- the 5 ' oligonucleotide primer included an EcoRV site and the codons needed to complete the ICAM-1 leader sequence.
- the 3 ' oligonucleotide primer included codons for six histidine residues, a stop codon, and Hina U and EcoRV restriction sites.
- the amplification product from this PCR was digested with EcoRV to produce a blunt-ended sequence which was then ligated into the blunt-ended Sma ⁇ - digested pBS + linearized vector.
- the entire sequence containing the ICAM-1 leader sequence 5 ' to the ICAM-4 domains 1 through 6 was removed from the construct with BglR and Hindm digestion and the purified ICAM- 1 /ICAM-4 fusion sequence cloned directly into a BgM/Hind ⁇ I- digested pBluesac HI vector (Invitrogen).
- Protein production by the recombinant virus was assayed for by ⁇ LISA, initially using immune sera from mice immunized with rat ICAM-4 domain-2/GST fusion protein described in Example 5. In later work, monoclonal antibodies generated from those mice were used to purify ICAM-4 protein produced by the recombinant baculovirus in SF9 cells.
- Rat ICAM-4 domains 1-6 were expressed in the baculovirus expression system as described in Example 7.
- the recombinant protein was purified using monoclonal antibody 103 A (as described in Example 6). Briefly, 30 mg of purified monoclonal 103 A (in 100 mM sodium borate, 500 mM sodium chloride) were coupled to three grams of Activated Cyanogen Bromide Sepharose 4B (Pharmacia, Piscataway, NJ). Baculovirus supernatant containing recombinant rat ICAM-4 (domains 1-6) was loaded on the Sepharose column overnight at 4°C.
- CMF-PBS calcium- magnesium-free phosphate buffered saline
- bound material was eluted in 50 mM citric acid, 500 mM NaCl pH 4.0.
- the sample was neutralized with 1/10 volume Tris pH 10 and stored at -20°C.
- the purified protein separated on SDS-PAGE appeared greater than 90% pure and migrated at approximately 80 kD. Mice were immunized with the purified recombinant rat ICAM-
- Example 6 4 domains 1-6 protein in a similar manner as described in Example 6.
- the spleen from mouse #1945 was used for fusion #127.
- the fusion protocol was as described in Example 6.
- the fusion wells were screened by ELISA on the recombinant ICAM-4 protein.
- the secondary screen included immunocyto- chemistry on rat brain sections (as below described in Example 9).
- Four additional antibodies specific for rat ICAM-4 were cloned out of this fusion: 127A, 127E, 127F and 127H.
- the immunocytochemical staining pattern of each antibody on rat brain sections was the same as observed with monoclonal antibody 103 A (see Example 9).
- the monoclonal antibodies were tested for their ability to bind the Dl/GST and D2/GST fusion proteins (described in Example 5).
- Monoclonal antibody 127A recognized the Dl/GST fusion protein and 127H recognized the D2/GST fusion protein.
- Hybridomas 127 A and 127H were deposited May 31 , 1995 and June 1 , 1995, respectively, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, and assigned Accession Numbers HB1 1905 and HB1191 1 , respectively.
- Immunocytochemistry with monoclonal antibody 103A was performed to localize the protein production within the rat brain.
- a brain was harvested from a normal adult female Lewis rat, sagittally sectioned, and washed in RNase-free IX PBS on ice for 30 min. The brain sections were then placed in Tissue Tek II cryomolds (Miles Laboratories, Inc. , Naperville, IL) with a small amount of O.C.T. compound (Miles, Inc. , Elkhart, IN). The brains were centered in the cryomold, the cryomold filled with OCT compound, then placed in a container with 2- methylbutane (Aldrich Chemical Company, Inc. , Milwaukee, WI) and the container placed in liquid nitrogen. Once the tissue and OCT compound in the cryomold were frozen, the blocks were stored at -80 °C until sectioning.
- the tissue was sectioned at 6 ⁇ m thickness, adhered to
- Vectabond (Vector Laboratories, Inc. , Burlingame, CA) coated slides and allowed to air-dry at room temperature overnight until use.
- the sections were fixed in ethyl ether (Malinckrodt, Paris, KY) for 5 minutes at room temperature. Once the slides were removed from the ether, the reagent was allowed to evaporate.
- Each tissue section was blocked with 150 ⁇ l 50% Normal rat serum (Sigma) and 2 % bovine serum albumin (BSA) (Sigma) in IX PBS (made with sodium phosphates only) for 30 minutes at room temperature.
- BSA bovine serum albumin
- the solution was gently blotted from the sections and the purified supernatant antibody 103 A (1.65 mg/ml) was diluted 1 : 10 in the blocking solution and 150 ⁇ l applied to each tissue section.
- the slides were placed in a humidity chamber and incubated at 4°C overnight. The next day the antibody solution was blotted gently from the section and the slides washed three times in IX PBS for four minutes in each wash. The excess PBS was aspirated from the slide and 100 ⁇ l of the secondary, rat anti mouse-biotin conjugated antibody (Jackson Immuno- Research Laboratories), diluted 1 : 100 in a solution of 10% normal rat serum and 2 % BSA in IX PBS, applied to the tissues.
- Incubation was allowed to proceed for one hour at room temperature.
- the sections were washed two times in IX PBS for four minutes in each wash, then 100 ⁇ l of ABC reagent from an Elite Rat IgG Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA), prepared according to the product insert, was applied to each section.
- Incubation was allowed to proceed for 30 minutes at room temperature.
- the slides were washed two times in IX PBS (four minutes each wash) and 150 ⁇ l of Vector VIP Peroxidase Substrate Solution (Vector Laboratories, Inc. , Burlingame, CA) applied to each section for approximately ten minutes.
- rat ICAM-4 is expressed in the neuronal cells of the hippocampus. Staining pattern suggested that the protein might be limited to the neuronal processes (dendrites). Brain sections stained in a similar manner with an irrelevant antibody or second step reagent alone do not show the distinct expression pattern seen with MAb 103 A. EXAMPLE 10 Cloning of a Human ICAM-4 Genomic DNA
- ICAM-4 and ICAM-1 were located within 5 kb of each other and this information was utilized in an attempt to clone the human homologue of ICAM-4.
- Genome Systems Inc. (St. Louis, MO) amplified fragments in a human PI library by PCR using human ICAM-1 domain 3 primers, a sense primer designed complementary to human ICAM-1 domain 3 (H-1/D3 S) and an antisense primer designed complementary to human ICAM-1 domain 3 (H- 1/D3 AS). These primers are set forth in SEQ ID NOs: 22 and 23, respectively.
- the fragments of genomic DNA corresponding to domains 2-5 of human ICAM-4 (described in Example 10) were used as probes to screen a ⁇ gtlO Human hippocampus cDNA library (Clontech, Palo Alto, CA).
- the library screening protocol was essentially as described in Example 1.
- the longest human ICAM-4 clone (#18) that was found in that library was only 992 bp (SEQ ID: 24) and corresponded to roughly the middle of the predicted 3 kb gene.
- the 992 bp DNA insert from clone 18 (SEQ ID: 24) was used as a probe to screen a ⁇ ZAPLI human hippocampus cDNA library (Stratagene, La Jolla, CA). This library yielded a number of positive clones.
- the longest clone, #34. was 2775 bp (SEQ ID: 25). Based on alignments to the full length rat ICAM-4, it was predicted that this clone was missing the leader sequence and approximately 30 bp at the 5 ' end of domain 1. The poly A + tail at the 3 ' end was missing, but the translation stop codon was present.
- a fragment of DNA corresponding to the first 3 domains was used as a probe to screen a ⁇ gtlO cDNA library derived from human cerebral cortex (Clontech, Palo Alto, CA).
- One clone, 16-1 was identified as having 1557 bp, and included 39 bp of 5 ' untranslated DNA, a leader sequence and sequence information through the fifth domain.
- Overlapping clones #34 SEQ ID: 25
- 16-1 SEQ ID: 26
- the full length gene is 2927 bp long and encodes a 924 amino acid protein.
- the ICAM-4 nucleotide sequence is set out in SEQ ID NO: 27 and the amino acid sequence is set out in SEQ ID NO: 28.
- Sequence alignment with the full length rat ICAM-4 gene revealed an overall DNA sequence identity of 82 % and 85 % identity at the amino acid level.
- the apparent 9 Ig like extracellular domain structure of the protein is conserved between rat and human.
- the leader sequence extends from amino acid 1 to 28; domain 1 from amino acid 29 to 117; domain 2 from amino acid 118 to 224; domain 3 from amino acid 225 to 320; domain 4 from amino acid 321 to 405; domain 5 from amino acid 406 to 488; domain 6 from amino acid 489 to 570; domain 7 from amino acid 571 to 663; domain 8 from amino acid 664 to 743; domain 9 from amino acid 744 to 837; the transmembrane region from amino acid 838 to 857 and the cytoplasmic tail from amino acid 858 to 924.
- Human ICAM-4 in addition to being genetically linked to ICAM-1 and ICAM-R, also showed certain common structural features that group them together as a family of molecules.
- a domain by domain alignment of HuICAM-4 with the other members of the ICAM family shows varying degrees of homology.
- Domain 1 amino acid sequence of HuICAM-4 is 21 , 30 and 26% identical to domain 1 of ICAMs 1 , 2 and 3 respectively.
- Domain 2 of HuICAM-4 is 61 , 39 and 62 % identical to ICAMs 1 , 2 and 3 respectively.
- Domain 3 of HuICAM-4 is 50 and 65% identical to ICAMs 1 and 3 respectively.
- Domain 4 of HuICAM-4 is 54 and 64% identical to ICAMs 1 and 3 respectively.
- HuICAM-4 Domains 5-8 of HuICAM-4 are most homologous to the fifth domains of ICAM-1 and 3, with percent identities ranging from 33-47 for ICAM-1 domain 5 and 21-31 for IC.AM-R dom.ain 5.
- the ninth domain of HuICAM-4 aligns poorly with the other members of the ICAM f.amily but is homologous to domains 3 (24% identical) and 6 (23 % identical) of HuICAM-1.
- MTN human multiple tissue Northern
- Clontech Clontech (Palo Alto, CA). These contained at least 2 ⁇ g of poly A + RNA from 16 different human tissues (as shown in Table 1) run on a denaturing formaldehyde 1.2% agarose gel and transferred to nylon membrane. The blots were prehybridized for three hours at 42°C in 10 ml of a solution containing 5X SSPE, 10X Denhardts solution, 50% formamide, 2 % SDS and 100 ⁇ g/ml denatured salmon sperm DNA. The blots were hybridized in the above solution with a radiolabeled human ICAM-4 probe (clone #18, SEQ ID: 24) for 16 hours at 42°C.
- a radiolabeled human ICAM-4 probe (clone #18, SEQ ID: 24) for 16 hours at 42°C.
- RNA quality and quantity loaded was checked by probing the blots with a ⁇ actin probe.
- Human ICAM-4/IgGl fusion proteins expression plasmids were constructed to produce proteins for generating monoclonal antibodies and for use in adhesion assays to identify potential ICAM-4 ligands. Two constructs were made; the first included DNA encoding domains 1-3 of HuICAM-4 and the second, domains 4-8. Both were linked to the Fc region of human IgGl in vector pDCSl that uses the cytomegalovirus (CMV) promoter to drive expression and the signal sequence from IgG4 to facilitate secretion of the molecules.
- CMV cytomegalovirus
- PCR primers (shown below as SEQ ID NOs: 29-32) were designed to generate the necessary DNA fragments for sub-cloning.
- the "sense" primer for the 5 ' end of domain 1 (HI4-Dl(s), SEQ ID NO: 29) was designed to fill in 30 base pairs of domain 1 missing in clone #34.
- Primers HI4-D1(S) (SEQ ID NO: 29) and HI4-D3(AS) (SEQ ID NO: 30) were used to generate a DNA fragment encoding domains 1-3 of human ICAM-4, corresponding to a region in SEQ ID NO: 1 from nucleotide 130 to nucleotide 996.
- Primers HI4-D3(S) (SEQ ID NO: 31) and HI4-D8(AS) (SEQ ID NO: 32) were used to generate a DNA fragment encoding domains 4-8 of human ICAM-4, corresponding to a region in SEQ ID NO: 30 from nucleotide 997 to nucleotide 2268.
- All oligonucleotides contain spacer nucleotides (underlined, below) at the 5 ' end to permit restriction digestion.
- HI4-D8(AS) (SEQ ID NO: 32) ATTTCTCTCGAGTTCCACGCCCACAGTGACGG
- PCR reactions were carried out in a 50 ⁇ l volume using buffers supplied by Perkin Elmer with the AmpliTaq enzyme. Primers were added at a final concentration of 10 ⁇ g/ml and all four dNTPs were included at 2 mM. The reactions were continued through 30 cycles of denaturation (94 °C for four minutes), annealing (50 °C for two minutes) and extension (72 °C for one minute). PCR products were visualized on agarose gels and an aliquot of each reaction was used to subclone the PCR products into vector pCRII (Invitrogen, SanDiego, CA). Sequence analysis was performed to detect possible errors resulting from the amplification process and to confirm proper orientation.
- pCRII Invitrogen, SanDiego, CA
- Appropriate clones were digested with BamHl and Xh ⁇ l and fragments separated with agarose gel electrophoresis. Purified fragments were ligated into a pDCS 1 vector previously digested with BamHl and Xh ⁇ l and the resulting plasmids were sequenced to confirm proper orientation and reading frame.
- Human ICAM-4 domains 1-3 and 4-8/IgGl fusion proteins were obtained following transient transfection of the expression plasmids into COS7 cells and isolation of the secreted protein from the culture media. Transfection was carried out as follows. Adherent COS7 cells at approximately 50- 60% confluence were washed with CMF-PBS and subsequently contacted with 10-15 ⁇ g of plasmid DNA in 7.5 ml serum-free DMEM media (Gibco, Gaithersburg, MD) containing 6 ⁇ l of 0.25 M chloroquine (Sigma, St. Louis, MO). An additional 7.5 ml of serum-free media containing 150 ⁇ l of DEAE dextran (50 mg/ml) (Sigma, St.
- the fusion proteins were eluted into one ml fractions using 50 mM citric acid pH 3.0 and each fraction was neutralized with 1/10 volume 1 M Tris, pH 9.5. Protein concentration was determined by OD 280 , and purity was determined using SDS-PAGE.
- EXAMPLE 14 Monoclonal Antibody Production The purified protein described in Example 13 was utilized to generate monoclonal antibodies using an immunization protocol as described in Example 6.
- the spleen from mouse #2250 (immunized with HuICAM-4 Dl- 3/IgGl) was used for fusion 172 and the spleen from mouse #2272 (immu- nized with HuICAM-4 D4-8/IgGl) was used for fusion 173.
- the fusion protocol utilized was as described in Example 6. Fusion plates were screened by ELISA (essentially as described in Example 6) using each HuICAM-4/IgGl fusion protein. Fusion well supernatants that recognized the immunogen protein, and no other, were considered for cloning. Immunocytochemistry on human hippocampus sections was used as a secondary screen.
- clone 173E which was derived from the HuICAM-4 D4-8/IgGl immunized mouse.
- Hybridoma 173E was deposited June 1, 1995 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, and assigned Accession Number HB11912.
- hybridoma cell lines producing antibodies 1791 and 179H were deposited on June 10, 1996 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville Maryland, 20852 and assigned Accession Numbers HB 12123 and HB 12124, respectively. Additional fusions are similarly performed to generate other antibodies specifically immunoreactive with particular ICAM-4 regions.
- the six monoclonal antibodies from fusion 179 were tested in various combinations for their ability to capture and detect soluble ICAM-4 in solution.
- Antibody 1791 was coated on Immulon 4 (Dynatech) 96 well plates at 3 ⁇ g/ml, 125 ⁇ l/well for two hours at 37°C.
- the antibody solution was removed by aspiration and the wells were blocked for 30 minutes at room temperature with 300 ⁇ l of blocking solution containing 5 % Teleostean gelatin in calcium-free, magnesium-free PBS (CMF-PBS).
- the blocking solution was removed by aspiration, a 100 ⁇ l of sample fluid diluted in Omni Diluent (CMF-PBS, 1 % gelatin, and 0.05 % Tween 20) was added to each well, and the mixture incubated at 37 °C for 30 minutes.
- PBST CMF-PBS, 0.05 % Tween 20
- Antibody 179H was biotinylated at 1.5 mg/ml using NHS-LC-Biotin (Pierce) following suggested manufacturer's protocol, diluted 1 :2000, and added to the wells (100 ⁇ l/well). The resulting mixture was incubated for 30 minutes at 37°C and the plates washed three times with PBST. Streptavidin-HRP (Pierce) was added (100 ⁇ l, 0.25 ⁇ g/ml) to each well and this mixture incubated at 37°C for 30 minutes.
- the plates were washed four times with PBST before addition of 100 ⁇ l of Tetramethylbenzidine (Sigma) (10 mg/ml stock in DMSO) diluted 1 : 100 in buffered substrate (13.6 g/L sodium acetate trihydrate, pH to 5.5 with 1 M citric acid, with 150 ⁇ l/L 30% hydrogen peroxide added just prior to developing).
- the reaction was allowed to develop for 30 minutes at room temperature in the dark, after which the reaction was stopped with addition of 50 ⁇ l/well 15 % H 2 S0 .
- the absorbance was read at 450 nm.
- ICAM-4 mRNA Levels in Hippocampus in a Rat Model of Epilepsy Levels of rat ICAM-4 mRNA expressed were assessed in hippocampus of rats treated in a manner to create a kindling epileptogenesis animal model [Lothman, et al., Brain Res. 360:83-91 (1985)].
- the rat hippocampus is stimulated with a series of subconvulsive electric shocks through an electrode implanted in the region of the brain which gradually elicits severe behavioral seizures.
- the kindling process involves twelve stimulations per day administered every other day for eight days. Once fully kindled, a single stimulus can elicit behavioral seizures and histologic changes that are similar to human epilepsy.
- Fully kindled rats received two stimulations per day over a two week period and animals were sacrificed 24 hours after the last stimulation. The hippocampus was removed and dissected for RNA preparation.
- Serum ICAM-4 Concentration as a Marker for Neurodegenerative Disorders
- Circulating serum concentrations of ICAM-4 were assessed as a possible indicator for various neurodegenerative disorders. Serum and/or plasma samples from anonymous donors were assayed as described in
- Example 16 above and compared to samples drawn from control donors with no previous history of neurological disorders.
- Control Donors In order to establish a baseline average for circulating ICAM-4 in normal healthy individuals, serum samples from 100 donors were examined. The results showed that twelve individuals (12 %) had circulating levels of ICAM-4 greater than 10 ng/ml. Of these twelve, the ICAM-4 concentration in five samples averaged 10-20 ng/ml, three samples showed an average ICAM-4 concentration of 20- 100 ng/ml, two samples showed ICAM-4 levels between 100-500 ng/ml, and two samples contained ICAM-4 at a concentration in excess of 500 ng/ml.
- the serum concentration of ICAM-4 in samples from twenty patients with Temporal Lobe Epilepsy (TLE) was measured and compared to serum samples from control group patients that had experienced Grand Mai Seizures (38 different patients), Syncope (8 patients) or were normal healthy donors (20 individuals).
- the assay method described in Example 15 was again employed and the results expressed as ng/ml relative to the internal standard used for the assay, soluble HuICAM-4 Dl-3 recombinant protein (described in Example 13). Serum from all 20 patients with TLE had measurable levels of
- ICAM-4 with an average of approximately 140 ng/ml. In serum samples from all 3 control groups, including the Grand Mai Seizure group, ICAM-4 concentration averaged below 10 ng/ml. These observations suggest that an individual's ICAM-4 serum level may represent a biochemical marker which can distinguish between focused seizures, like those experienced in TLE, and more generalized Grand Mai Seizures.
- Serum concentration of ICAM-4 in the sera from a limited number of AIDS patients was also examined.
- the patients were grouped according to CD4 counts and the presence of any signs of dementia.
- a first group comprised sixteen early stage, asymptomatic patients with CD4 counts greater than 500 were tested.
- a second group comprised seven later stage patients with CD4 counts less than 300; signs of dementia were not determined for this group.
- the last group comprised nine late stage AIDS patients, each showing signs of dementia.
- ICAM-4 levels in the blood may reflect damage to the neurons that normally express it.
- ICAM-4 levels in the blood may reflect damage to the neurons that normally express it.
- Alzheimer's disease is associated with extensive neuronal damage in the regions of the telencephalon where ICAM-4 is expressed.
- Assessment of ICAM-4 levels in serum from patients with the Early-onset Familial forms of the disease, as well as patients with the sporadic form of the disease may provide a marker for the various stages of the disease thereby permitting assessment of possible therapeutic interventions.
- cortical dementias such as Pick's disease, diffuse cortical Lewy body disease, and frontal lobe degeneracy
- serum ICAM-4 concentration in patients suffering from a subcortical dementia including Parkinson's disease, Huntington's disease, and progressive supranuclear, may be elevated as a result of common pathological indications of this class of disorders.
- a number of the primary psychiatric disorders such as depression, schizophrenia and psychosis, are characterized in part by degrees of neurodegeneration that might be associated with detectable levels of ICAM-4 in the blood.
- ICAM-4 may be associated with a number of nongenetic dementias arising from infections, vasculitis, metabolic and nutritional disorders (e.g. , thyroid, vitamin B12 deficiency), vascular disorders (multiple infarct, lacunar state, Binswanger's disease), toxic encephalopathies (e.g. , exposure to carbon monoxide, heavy metals or other industrial pollutants) and tumors.
- metabolic and nutritional disorders e.g. , thyroid, vitamin B12 deficiency
- vascular disorders multiple infarct, lacunar state, Binswanger's disease
- toxic encephalopathies e.g. , exposure to carbon monoxide, heavy metals or other industrial pollutants
- ICAM-4 gene expression is spatially and temporally regulated, with expression limited to the most anterior or ventral region of the brain, the telencephalon.
- the nucleotide region 5 ' to human ICAM-4 coding sequences was examined.
- the complete sequence for this upstream region is set out in SEQ ID NO: 33.
- the "A" in ATG start codon (numbered in SEQ ID NO: 33 as nucleotides 1685-1687) is designated the + 1 nucleotide and the nucleotide immediately 5 ' to the A + ! nucleotide is designated -1.
- the entire sequence is shown as extending from nucleotide -1684 to nucleotide +3, corresponding to numbering in the Sequence Listing nucleotide 1 to nucleotide 1687.
- oligonucleotides were synthesized and used in PCR to generate DNA molecules of various lengths within the upstream regulatory region.
- Each oligonucleotide set out in Table 3 contained a spacer region (shown in italics) approximately 6-10 bp to allow enzymatic digestion of the PCR product, an Nhel or H dHI restriction site (shown in bold), and a specific hybridization primer sequence (underlined).
- the oligonucleotide names contain numbers that designate its location within the upstream regulatory region.
- oligonucleotides were paired as shown in Table 4 to generate DNA fragments containing specific regions of the upstream regulatory region.
- the restriction sites and spacer region generated within each oligonucleotide allowed for enzymatic digestion and subsequent directional cloning of individual PCR products into the pGL3 Basic Vector (Promega, Madison, WI) which contains a luciferase reporter gene immediately downstream of a multiple cloning site (MCS).
- MCS multiple cloning site
- Promoter activity cloned into the MCS region of the vector drives expression of the luciferase reporter gene in transfected cell lines, and light production from expressed luciferase can be measured as an indicator of promoter activity.
- the pGL3 Basic Vector has TABLE 3
- each expression construct was verified by restriction analysis and DNA sequencing. Plasmids containing each of the amplified sequences described in Table 4 were transfected into mammalian cells using a Transfection MBS Mammalian Transfection Kit (Stratagene, La Jolla, CA) according to manufacturer's suggested protocol. Each plasmid was introduced into two different cell lines, COS 7 and NT2 Precursor Cells (Ntera2/Dl from Stratagene).
- COS 7 cells are a commonly used simian fibroblast-like cell line transformed with SV40 making them well suited for driving expression of a gene under control of the SV40 promoter in cells transfected with the positive control pGL3 Promoter Vector.
- NT2 precursor cells are a committed neuronal precursor cell line, and while they do not express ICAM-4, they may be more representative of a cell type that does express ICAM-4.
- Each well of a 6 well flat bottom tissue culture plate (Falcon) was seeded with 2.5xl0 5 cells. Transfections of COS 7 and NT2 cells were done side by side in duplicate using 5 ⁇ g of plasmid DNA for each well. The cells were cultured at 37°C for 48 hours, lysed and assayed for luciferase activity with a Luciferase Assay System (Promega).
- Results of the experiment indicate a high level of promoter activity contained within the -408 through -19 and -480 through -19 regions of the upstream regulatory region of ICAM-4 in NT2 cells. Because NT2 cells are of neuronal origin, they may express certain transcription factors recognizing the ICAM-4 promoter that are not found in other cell types. The highest level of promoter activity in COS cell transfectants was obtained with the plasmid containing nucleotides -560 through -19. While the positive control pGL3 Promoter Vector worked well in COS cells, it showed very low promoter activity in NT2 cells, thus illustrating a cell type specific preference for certain promoter sequences.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK98953249T DK0956508T3 (en) | 1997-10-02 | 1998-10-02 | ICAM-4 for diagnostic applications thereof |
EP98953249A EP0956508B1 (en) | 1997-10-02 | 1998-10-02 | Icam-4 and diagnostic uses thereof |
AT98953249T ATE237140T1 (en) | 1997-10-02 | 1998-10-02 | ICAM-4 AND ITS DIAGNOSTIC USES |
CA002273195A CA2273195A1 (en) | 1997-10-02 | 1998-10-02 | Icam-4 and diagnostic uses thereof |
JP52214699A JP2001508181A (en) | 1997-10-02 | 1998-10-02 | ICAM-4 and its diagnostic use |
AU10669/99A AU735917B2 (en) | 1997-10-02 | 1998-10-02 | ICAM-4 and diagnostic uses thereof |
IL13022898A IL130228A0 (en) | 1997-10-02 | 1998-10-02 | ICAM-4 and diagnostics uses thereof |
BR9806294-8A BR9806294A (en) | 1997-10-02 | 1998-10-02 | Selection process for neuropathology in an individual |
DE69813181T DE69813181T2 (en) | 1997-10-02 | 1998-10-02 | ICAM-4 AND ITS DIAGNOSTIC USE |
NO992666A NO992666L (en) | 1997-10-02 | 1999-06-02 | ICAM-4 and its diagnostic use |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82768992A | 1992-01-27 | 1992-01-27 | |
US88972492A | 1992-05-26 | 1992-05-26 | |
US89406192A | 1992-06-05 | 1992-06-05 | |
US926693A | 1993-01-22 | 1993-01-22 | |
US10285293A | 1993-08-05 | 1993-08-05 | |
US08/245,295 US5700658A (en) | 1992-01-27 | 1994-05-18 | ICAM-4 materials and methods |
US94286797A | 1997-10-02 | 1997-10-02 | |
US08/942,867 | 1997-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999018441A1 true WO1999018441A1 (en) | 1999-04-15 |
Family
ID=27567423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/020876 WO1999018441A1 (en) | 1992-01-27 | 1998-10-02 | Icam-4 and diagnostic uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1999018441A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992022323A1 (en) * | 1991-06-11 | 1992-12-23 | Center For Blood Research, Inc. | Intercellular adhesion molecule-3 and its binding ligands |
-
1998
- 1998-10-02 WO PCT/US1998/020876 patent/WO1999018441A1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992022323A1 (en) * | 1991-06-11 | 1992-12-23 | Center For Blood Research, Inc. | Intercellular adhesion molecule-3 and its binding ligands |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5869262A (en) | Method for monitoring an inflammatory disease state by detecting circulating ICAM-R | |
US5977303A (en) | Mammalian cell surface antigens | |
US5837822A (en) | Humanized antibodies specific for ICAM related protein | |
UA76936C2 (en) | Human monoclonal antibody binding the antigen-4 of cytotoxic t-lymphocyte (ctla-4), nucleic acid, cell line, method of obtaining transgenic mammal, method to increase producing il-2 or ifn-? in the t-cells of a patient, method to treat and pharmaceutical composition used in treatment of cancer, inflammation or autoimmune disease, including the antibody | |
CA2095115A1 (en) | T-cadherin adhesion molecule | |
US20030199423A1 (en) | ICAM-related protein | |
US5663293A (en) | ICAM-related protein | |
US5753502A (en) | Neuron-specific ICAM-4 promoter | |
US5532127A (en) | Assay for 1-CAM related protein expression | |
US6040176A (en) | Antibodies to ICAM-related protein | |
US5773293A (en) | Anti-ICAM-4 antibodies and hybridomas | |
EP0789763B1 (en) | Icam-4 materials and methods | |
US5770686A (en) | ICAM-related protein fragments | |
EP0956508B1 (en) | Icam-4 and diagnostic uses thereof | |
US5852170A (en) | ICAM-4 materials and methods | |
WO1999018441A1 (en) | Icam-4 and diagnostic uses thereof | |
US5989843A (en) | Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein | |
JP4537507B2 (en) | Monoclonal antibody against connective tissue growth factor and pharmaceutical use thereof | |
US6818743B1 (en) | I-CAM related protein | |
US5700658A (en) | ICAM-4 materials and methods | |
US20030068659A1 (en) | ICAM-4 materials and methods | |
AU1117099A (en) | ICAM-6 materials and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98802232.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU IL JP MX NO PL RU SK |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2273195 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1999 522146 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/005097 Country of ref document: MX Ref document number: 10669/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998953249 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1998953249 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 10669/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998953249 Country of ref document: EP |